Product Name :
Sulopenem
Description:
Sulopenem (CP-70429) is an orally active, parenteral penem antibiotic with broad-spectrum activities against Gram-positive and Gram-negative bacteria. Sulopenem has the potential for urinary tract infections and intra-abdominal infections treatment. Sulopenem is inactive against Pseudomonas aeruginosa and Xanthomonas maltophilia.
CAS:
120788-07-0
Molecular Weight:
349.45
Formula:
C12H15NO5S3
Chemical Name:
(5R,6S)-6-[(1R)-1-hydroxyethyl]-7-oxo-3-{[(1R,3S)-1-oxo-1λ⁴-thiolan-3-yl]sulfanyl}-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid
Smiles :
C[C@@H](O)[C@@H]1[C@H]2SC(S[C@@H]3C[S@](=O)CC3)=C(C(O)=O)N2C1=O
InChiKey:
FLSUCZWOEMTFAQ-PRBGKLEPSA-N
InChi :
InChI=1S/C12H15NO5S3/c1-5(14)7-9(15)13-8(11(16)17)12(20-10(7)13)19-6-2-3-21(18)4-6/h5-7,10,14H,2-4H2,1H3,(H,16,17)/t5-,6+,7+,10-,21-/m1/s1
Purity:
≥98% (or refer to the Certificate of Analysis)
Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis
Storage Condition :
Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.{{Carmustine} medchemexpress|{Carmustine} Cell Cycle/DNA Damage|{Carmustine} Protocol|{Carmustine} Formula|{Carmustine} manufacturer|{Carmustine} Autophagy}
Shelf Life:
≥12 months if stored properly.
Stock Solution Storage:
0 – 4 oC for 1 month or refer to the Certificate of Analysis.
Additional information:
Sulopenem (CP-70429) is an orally active, parenteral penem antibiotic with broad-spectrum activities against Gram-positive and Gram-negative bacteria.{{Rilotumumab} web|{Rilotumumab} Protein Tyrosine Kinase/RTK|{Rilotumumab} Technical Information|{Rilotumumab} Formula|{Rilotumumab} supplier|{Rilotumumab} Autophagy} Sulopenem has the potential for urinary tract infections and intra-abdominal infections treatment.PMID:32783899 Sulopenem is inactive against Pseudomonas aeruginosa and Xanthomonas maltophilia.|Product information|CAS Number: 120788-07-0|Molecular Weight: 349.45|Formula: C12H15NO5S3|Chemical Name: (5R,6S)-6-[(1R)-1-hydroxyethyl]-7-oxo-3-{[(1R,3S)-1-oxo-1λ⁴-thiolan-3-yl]sulfanyl}-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid|Smiles: C[C@@H](O)[C@@H]1[C@H]2SC(S[C@@H]3C[S@](=O)CC3)=C(C(O)=O)N2C1=O|InChiKey: FLSUCZWOEMTFAQ-PRBGKLEPSA-N|InChi: InChI=1S/C12H15NO5S3/c1-5(14)7-9(15)13-8(11(16)17)12(20-10(7)13)19-6-2-3-21(18)4-6/h5-7,10,14H,2-4H2,1H3,(H,16,17)/t5-,6+,7+,10-,21-/m1/s1|Technical Data|Appearance: Solid Power|Purity: ≥98% (or refer to the Certificate of Analysis)|Solubility: DMSO : 83.33 mg/mL (238.46 mM; Need ultrasonic).|Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis|Storage Condition: Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.|Shelf Life: ≥12 months if stored properly.|Stock Solution Storage: 0 – 4 oC for 1 month or refer to the Certificate of Analysis.|Drug Formulation: To be determined|HS Tariff Code: 382200|How to use|In Vitro:|Sulopenem has the potential for uncomplicated and complicated urinary tract infections and intra-abdominal infections treatment, including multidrug-resistant (MDR) infections and infections attributable to quinolone-nonsusceptible and/or extended-spectrum β-lactamase (ESBL)-producing Gram-negative bacilli. Sulopenem inhibits the growth of most isolates of aerobic and anaerobic Gram-positive and Gram-negative bacteria, including methicillin-susceptible Staphylococcus aureus, Streptococcus pneumoniae (penicillin-susceptible and -resistant isolates), group A and B β-hemolytic streptococci, Listeria monocytogenes, Enterobacteriaceae, Haemophilus influenzae, and Moraxella catarrhalis but excluding P. aeruginosa and Stenotrophomonas maltophilia, at a concentration of ≤1 μg/mL.|In Vivo:|The protective effects of Sulopenem in murine experimental systemic infections are superior to those of Imipenem/Cilastatin. In murine experimental mixed infection with Escherichia coli and Bacteroides fragilis, Sulopenem has lower ED50. In guinea pigs experimental lung infection with Klebsiella pneumoniae, Sulopenem is more effective than CZON or Cefotiam.|Products are for research use only. Not for human use.|